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Abstract: Retinal vein occlusion (RVO) is a prevalent retinal vascular disease, second only to 
diabetic retinopathy. Previously there was no treatment for central retinal vein occlusion (CRVO) 
and patients were simply observed for the development of severe complications, generally 
resulting in poor visual outcomes. The only treatment for branch vein occlusion (BRVO) was 
grid laser photocoagulation, which reduces edema very slowly and provides benefit in some, 
but not all patients. Within the past year, clinical trials have demonstrated the effects of three 
new pharmacologic treatments, ranibizumab, triamcinolone acetonide, and dexamethasone 
implants. The benefit/risk ratio is best for intraocular injections of ranibizumab, making this 
first-line therapy for most patients with CRVO or BRVO, while intraocular steroids are likely 
to play adjunctive roles. Standard care for patients with RVO has changed and will continue to 
evolve as results with other new agents are revealed.
Keywords: vascular endothelial growth factor, triamcinolone acetonide, dexamethosone 
implant, sustained release, vascular leakage, ischemia
Introduction
There are two types of retinal vein occlusions (RVO), central retinal vein occlusion 
(CRVO) and branch retinal vein occlusion (BRVO). In CRVO, there is obstruction of 
the major outflow channel of the eye, resulting in effects throughout the entire retina, 
including hemorrhages; cotton wool patches, which represent nerve layer infarcts; 
edema; and capillary occlusion. Hemorrhages can vary from dense and almost conflu-
ent to sparse and scattered. Likewise, cotton wool patches and capillary occlusion can 
each range from little or none to extensive. In BRVO, a tributary of the central retinal 
vein is obstructed and only the portion of the retina that is drained by the tributary 
is affected. The more proximal the occlusion, the greater the area of retina affected; 
obstruction of the superior or inferior branch of the central retinal vein affects roughly 
half the retina and is called a hemiretinal vein occlusion. The consequences of BRVO 
are similar to those seen in CRVO (hemorrhages, cotton wool patches, edema, capil-
lary occlusion), but tend to be less severe because a portion of the retina has normal 
venous drainage.
Prevalence and incidence
The prevalence of RVO based upon several studies in the United States, Europe, Asia, 
and Australia is estimated to be 5.2 per 1,000.1 In the Beaver Dam Eye study, RVO 
accounted for 12% of eyes with visual acuity (VA) worse than 20/200.2 RVOs are the 
second most common type of retinal vascular disease, second only to diabetic retinopathy. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The incidence of RVOs is estimated to be 180,000 per year in 
the US and BRVOs account for nearly 80% of those.3
Risk factors and pathogenesis
Risk factors for CRVO include hypertension, diabetes 
mellitus, atherosclerosis, smoking, age . 65, open angle 
glaucoma, and conditions that promote a hypercoagulable 
state.4 Most of these risk factors lead to diffuse disease of the 
vascular endothelium and it is likely that there are anatomical 
or physiologic differences in the central retinal vein that pre-
dispose to thrombosis when its endothelium is compromised. 
Glaucoma appears to be one such factor; it is postulated that 
glaucoma-induced bowing of the lamina cribosa distorts the 
central retinal vein, altering blood flow in a way that promotes 
damage to the endothelium which promotes thrombosis. 
Histopathology has confirmed the presence of a thrombus 
in the central retinal vein in several cases.5 Local differences 
that predispose to thrombosis in nonglaucomatous eyes are 
unknown. Congenital or acquired kinking of the central 
retinal vein could be a predisposing factor, but there is no 
understanding of how or why it occurs.
Hypertension and atherosclerosis are risk factors for 
BRVO, and both cause thickening of arteriole walls. BRVO 
occurs at sites where retinal arterioles cross over veins and 
it appears that thickening of the arteriole wall compresses 
the vein, causes turbulent flow, damages endothelium, and 
promotes thrombosis.
The obstruction in venous outflow after CRVO or 
BRVO increases intraluminal venous pressure and causes 
transudation of plasma and blood, resulting in edema and 
hemorrhages throughout all or most of the retina for CRVO 
and throughout the drainage area of a BRVO. Severe edema 
appears to increase interstitial pressure and compromise 
arterial perfusion resulting in variable amounts of capillary 
occlusion and cotton wool patches. It is likely that differ-
ences in the amount of pre-existent arterial insufficiency from 
atherosclerosis determines differences in the amount of capil-
lary nonperfusion. In general, there is a wide spectrum with 
some patients showing very little nonperfusion and others 
showing larger areas of nonperfusion. Extensive nonperfu-
sion is associated with a poor prognosis and patients who 
have it are said to have ischemic BRVO or CRVO. In some 
patients, ischemia increases over time and they are viewed 
as undergoing a transition from nonischemic to   ischemic. 
Severe retinal ischemia can be complicated by retinal neo-
vascularization (NV), neovascular glaucoma, and a very poor 
visual outcome. Thus the amount of retinal ischemia is one 
of the major determinants of outcome.
Treatment
Laser photocoagulation
The use of laser photocoagulation to treat diabetic macular 
edema prompted its use in branch vein occlusion. The Branch 
Vein Occlusion Study was a prospective, randomized, mul-
ticenter trial that investigated the effects of grid laser treat-
ment in 139 eyes of patients with macular edema following 
BRVO occurring within 3–18 months of study entry, with 
best-corrected visual acuity (BCVA) of 20/40 or worse and 
sufficient clearing of retinal hemorrhage to allow safe laser 
photocoagulation.6 At the 3-year primary endpoint, patients 
treated with laser photocoagulation showed a statistically sig-
nificant mean improvement of 1.33 lines of vision compared 
with 0.23 lines in the control group. After publication of the 
Branch Vein Occlusion Study, grid laser therapy became the 
standard of care for BRVO. However, since many patients 
with BRVO present with BCVA of 20/80 or worse, an aver-
age improvement of 1.33 lines may leave affected patients 
with substantial visual disability in the affected eye. Since 
visual improvement occurs very slowly after laser treatment, 
there is a need for more effective treatments that provide 
rapid and complete restoration of vision.
The benefits seen in patients with BRVO with grid laser 
photocoagulation resulted in many clinicians trying grid 
laser therapy in CRVO and in some cases there appeared 
to be reduction in macular edema. However, the Central 
  Retinal Vein Occlusion Study demonstrated that despite 
some reduction in macular edema from grid laser therapy, 
there was no visual benefit compared to observation.7 Thus 
for many years, patients with CRVO were observed   watching 
for retinal or iris neovascularization and if that occurred, 
scatter photocoagulation was done.
Ranibizumab
Signs of retinal ischemia in patients with CRVO or BRVO 
such as cotton wool patches and capillary nonperfusion 
led to the hypothesis that VEGF released by ischemic 
retina   contributed to macular edema. The development of 
  ranibizumab, (Lucentis, Genentech, Inc, San Francisco, CA), 
a humanized, affinity-matured anti-VEGF antibody fragment 
that binds to and neutralizes all isoforms of VEGF-A and their 
biologically active degradation products8 made it   possible to 
test that hypothesis.
A small interventional pilot study in patients with CRVO 
or BRVO demonstrated that monthly injections of 0.3 mg or 
0.5 mg ranibizumab for 3 months caused a marked reduction 
in macular edema and a mean improvement in BCVA of 
approximately 15 letters in all ranibizumab treatment groups.9 Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Other pilot trials had similar results.10,11 This provided the 
rationale for two large multicenter trials, the Ranibizumab 
for the Treatment of Macular Edema after Central Retinal 
Vein OcclUsIon (CRUISE) Study12 and the RanibizumaB for 
the Treatment of Macular Edema following BRAnch Retinal 
Vein Occlusion (BRAVO) Study.13 In the CRUISE Study, 
392 patients with macular edema following central retinal 
vein occlusion (CRVO) were randomized to receive monthly 
intraocular injections of 0.3 mg (n = 132) or 0.5 mg (n = 130) 
of ranibizumab or sham injections (n = 130).
Patients were eligible if they had foveal-involved macular 
edema from a CRVO occurring within 12 months of study 
entry, BCVA of 20/40 to 20/320, and center subfield thick-
ness (CST) $250 µm (Stratus OCT3). Patients were excluded 
if they had a brisk afferent pupil defect, had   scatter laser 
photocoagulation within 3 months, an intraocular   injection 
of steroid or a VEGF antagonist within 3 months, or had 
an improvement of $10 ETDRS letters in BCVA between 
screening and baseline.
Baseline characteristics were well balanced among the 
three groups; the mean age was 68 years, mean BCVA 
was 20/100, the mean time from diagnosis of CRVO was 
3.3 months, and the mean center point thickness (CPT) was 
685 µm. At 6 months, the primary endpoint, mean change 
from baseline BCVA letter score was 12.7 and 14.9 in 
the 0.3 mg and 0.5 mg ranibizumab groups and 0.8 in the 
sham group (P , 0.0001). The percentage of patients who 
gained $ 15 letters in BCVA was 46.2% (0.3 mg) and 
47.7% (0.5 mg) in the ranibizumab groups and 16.9% in 
the sham group (P , 0.0001). The percentage of patients 
with a   Snellen equivalent BCVA of 20/40 or better was 
43.9% (0.3 mg) and 46.9% (0.5 mg) compared with 20.8% 
in the sham group (P , 0.0001). The percentage of patients 
with a Snellen equivalent BCVA of 20/200 or worse 
was 15.2% (0.3 mg) and 11.5% (0.5 mg) compared with 
27.7% in the sham group (P , 0.005). Based upon the NEI 
VFQ-25   survey, patients who received ranibizumab felt they 
had greater   improvement (improvement from baseline in 
NEI VFQ score: 7.1, 0.3 mg; 6.2, 0.5 mg: 2.8, sham). There 
was greater reduction of macular edema in the ranibizumab 
groups because CPT was reduced by 433.7 µm (0.3 mg) 
and 452.3 µm (0.5 mg) compared to 167.7 µm in the sham 
group. The percentage of patients with CPT # 250 µm at 
6 months was 75.0% (0.3 mg), 76.9% (0.5 mg), and 23.1% 
(sham, P , 0.0001). This study demonstrated that six ses-
sions of monthly i  njections of 0.3 mg or 0.5 mg reduced 
macular edema and provided substantial visual benefit in 
patients with CRVO.
In the BRAVO study, 397 patients with macular edema 
following branch retinal vein occlusion (BRVO) were ran-
domized to receive monthly intraocular injections of 0.3 mg 
(n = 134) or 0.5 mg (n = 131) of ranibizumab or sham injec-
tions (n = 132). Patients were eligible if they had foveal-
involved macular edema from a BRVO occurring within 
12 months of study entry, BCVA of 20/40 to 20/400, and 
CST $250 µm (Stratus OCT3). Exclusion criteria were the 
same as those in the CRUISE trial. Baseline characteristics 
were well balanced among the three groups; mean BCVA 
was 20/80, the mean time from diagnosis of BRVO was 
3.5 months, and the mean CPT was 520 µm. Starting at month 
3, patients were eligible for grid laser treatment if hemor-
rhages had cleared sufficiently to allow safe application of 
laser and the following criteria were met: Snellen equivalent 
BCVA # 20/40 or mean CST $ 250 µm, and compared with 
the visit 3 months before the current visit, the patient had 
a gain of ,5 letters in BCVA or a decrease of ,50 µm in 
mean CST. If rescue laser was not given at month 3, the same 
criteria were applied at month 4, and if rescue laser was not 
given at month 4, the criteria were applied at month 5.
At month 6, the primary endpoint, mean change from 
baseline BCVA letter score was 16.6 and 18.3 in the 0.3 mg 
and 0.5 mg ranibizumab groups and 7.3 in the sham group 
(P , 0.0001). The percentage of patients who gained $ 15 
letters in BCVA was 55.2% (0.3 mg) and 61.1% (0.5 mg) 
in the ranibizumab groups and 28.8% in the sham group 
(P , 0.0001). The percentage of patients with a Snellen 
equivalent BCVA of 20/40 or better was 67.9% (0.3 mg) 
and 64.9% (0.5 mg) compared with 41.7% in the sham group 
(P , 0.0001). The percentage of patients with a Snellen 
equivalent BCVA of 20/200 or worse was 1.5% (0.3 mg) 
and 0.8% (0.5 mg) compared with 9.1% in the sham group 
(P , 0.01). Based upon the NEI VFQ-25 survey, patients 
who received ranibizumab felt they had greater improve-
ment (improvement from baseline in NEI VFQ score: 9.3, 
0.3 mg; 10.4, 0.5 mg: 5.4, sham). There was greater reduction 
of macular edema in the ranibizumab groups because CPT 
was reduced by 337.3 µm (0.3 mg) and 345.2 µm (0.5 mg) 
compared to 157.7 µm in the sham group. The percentage of 
patients with CPT # 250 µm at month 6 was 91% (0.3 mg), 
84.7% (0.5 mg), and 45.5% (sham, P , 0.0001). More 
patients in the sham group (54.5%) received rescue grid 
laser therapy than in the 0.3 mg (18.7%) or 0.5 mg (19.8%) 
ranibizumab groups. There were no safety signals identified 
in either trial.
After the primary endpoint in the CRUISE and BRAVO 
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eye Snellen equivalent BCVA was #20/40 or mean CST 
was $250 µm, they received an injection of ranibizumab; 
patients in the ranibizumab groups received their assigned 
dose and patients in the sham group received 0.5 mg. In 
patients with CRVO, the mean number of ranibizumab 
  injections during the observation period was 3.9, 3.6, and 
4.2 in the 0.3 mg, 0.5 mg, and sham/0.5 mg groups; and 
the percentage of patients that did not receive any injec-
tions during the observation period was 7.0, 6.7, and 4.3, 
  respectively.14 At month 12 in the ranibizumab groups, the 
improvement from baseline in ETDRS letter score was 13.9, 
very similar to the month 6 results, indicating that vision is 
well maintained when injections are given only if there is 
recurrent or residual macular edema. Patients in the sham 
group showed substantial improvement during the observa-
tion period when they were able to receive ranibizumab; 
improvement from baseline in letter score was 0.8 at month 
6 and 7.3 at month 12. The percentage of patients who had 
an improvement from baseline BCVA letter score $ 15 
at month 12 was 47.0% (0.3 mg) and 50.8% (0.5 mg) in 
the ranibizumab groups, almost identical to the month 6 
results. In the sham group, 33.1% of patients improved 
from baseline $ 15 in letter score at month 12 compared to 
16.9% at month 6. At month 12, 43% of patients in the two 
ranibizumab groups had a Snellen equivalent BCVA of 20/40 
compared to 35% in the sham/0.5 mg group.
In patients with BRVO, the mean number of ranibizumab 
injections during the observation period was 2.9, 2.8, and 
3.8 in the 0.3 mg, 0.5 mg, and sham/0.5 mg groups; and 
the percentage of patients that did not receive any injec-
tions during the observation period was 17.2, 20.0, and 6.5, 
  respectively.15 At month 12 in the ranibizumab groups, the 
improvement from baseline in ETDRS letter score was 16.4 
(0.3 mg) and 18.3 (0.5 mg), very similar to the month 6 
results, indicating that vision is well maintained when injec-
tions are given only if there is recurrent or residual macular 
edema. Patients in the sham group showed substantial 
improvement during the observation period when they were 
able to receive ranibizumab; improvement from baseline in 
letter score was 7.3 at month 6 and 12.1 at month 12. The per-
centage of patients who had an improvement from baseline 
BCVA letter score $ 15 at month 12 was 55.2% (0.3 mg) 
and 61.1% (0.5 mg) in the ranibizumab groups, almost 
identical to the month 6 results. In the sham group, 43.9% 
of patients improved from baseline $ 15 in letter score at 
month 12 compared to 28.8% at month 6. At month 12, 67.9% 
(0.3 mg) and 64.4% (0.5 mg) of patients in the ranibizumab 
groups had a Snellen equivalent BCVA of 20/40 compared to 
56.8% in the sham/0.5 mg group. Thus, in both CRUISE and 
BRAVO, patients in the sham groups showed a substantial 
improvement in vision during the second 6 months when 
they were able to receive ranibizumab as needed, but their 
vision at month 12 was not as good as that in patients in the 
ranibizumab groups. This raises a question as to whether 
delay in treatment carries a visual penalty; hopefully this 
question will be answered by additional follow-up.
An important question is whether suppression of VEGF 
has deleterious effects on the retina, particularly in eyes that 
have retinal ischemia. In fact, some retina specialists have 
questioned whether suppression of VEGF might worsen 
macular ischemia. A detailed evaluation of fluorescein angio-
grams from BRAVO and CRUISE is needed to answer that 
question, but it is reassuring that loss of vision was rare in 
patients with RVO treated with ranibizumab and worsening 
of macular ischemia was not reported as an adverse event in 
any patients that received ranibizumab.
The only data available for time points longer than   
1 year are from relatively small pilot trials.16 Patients with 
BRVO given 3-monthly injections of ranibizumab had a mean 
improvement of 16.1 letters. After that, they were seen every 
2 months and were given an injection of ranibizumab if foveal 
thickness was $250 µm. At month 24, the mean improvement 
in BCVA was 17.8 letters, 60% had a Snellen equivalent of 
20/40 or better, and 65% had foveal   thickness # 250 µm. 
This indicates that visits every 2 months with injections of 
ranibizumab as needed is sufficient to control edema and 
maintain vision in patients with BRVO. Patients with CRVO 
given 3-monthly injections of ranibizumab had a mean 
improvement of 12.0 letters. After that, they were seen every 
2 months and were given an injection of ranibizumab if foveal 
thickness was $250 µm. At month 24, the mean improve-
ment in BCVA was 8.5 letters, 30% had a Snellen equivalent 
of 20/40 or better, and 30% had foveal thickness # 250 µm. 
This indicates that visits every 2 months with injections of 
ranibizumab as needed is not sufficient to control edema 
and maintain vision in patients with CRVO. At month 24, 
only 5 of 17 patients with BRVO and 3 of 14 patients with 
CRVO had complete resolution of edema and had not needed 
injections for at least 1 year. Two baseline characteristics that 
predicted a poor visual outcome in patients with BRVO or 
CRVO were the presence of macular edema for greater than 
1 year and extensive closure of perifoveal capillaries. Thus, 
the long-term outcomes for treatment of CRVO or BRVO 
with ranibizumab are excellent, but it may be difficult to 
completely wean patients off injections even after 2 years. 
Furthermore, compared to patients with BRVO, those with Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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CRVO on average require more frequent follow-up and a 
greater number of injections to control edema and maintain 
visual benefits.
intraocular steroids
The Standard Care vs Corticosteroid for Retinal Vein 
  Occlusion (SCORE) Studies compared intraocular injections 
of preservative-free triamcinolone acetonide (TA) to stan-
dard care in patients with macular edema due to CRVO17 or 
BRVO.18 In the CRVO study, 271 patients were randomized 
to receive 1 mg (n = 92) or 4 mg (n = 91) of TA or observation 
(n = 88). In the BRVO study, 411 patients were randomized 
to receive 1 mg (n = 136) or 4 mg (n = 138) of TA or grid 
laser (n = 137). In both studies, patients were eligible if they 
had foveal-involved macular edema from a CRVO occurring 
within 12 months of study entry, BCVA of 20/40 to 20/400, 
and CST $ 250 µm (Stratus OCT3). Patients were excluded 
if they had a prior intraocular steroid injection or vitrectomy, 
had laser photocoagulation within 3.5 months, or had a his-
tory of glaucoma or intraocular pressure (IOP) $ 25.
In the CRVO study, baseline characteristics were well bal-
anced among the three groups; the mean age was 68 years, 
mean BCVA was 20/100, the mean time from diagnosis 
of CRVO was 4 months, and the mean CPT was 659 µm. 
At month 12, the primary endpoint, mean change from base-
line BCVA letter score was -1.2 in the two TA groups and 
-12.1 in the observation group. The percentage of patients 
who gained $ 15 letters in BCVA was 26.5% (1 mg) and 
25.6% (4 mg) in the TA groups and 6.8% in the observation 
group. Reduction in CPT at month 12 was 196 µm (1 mg) and 
261 µm (0.5 mg) compared to 277 µm in the observation group. 
The percentage of patients with CPT # 250 µm at month 
12 was 32% (0.3 mg), 45% (4 mg), and 28%. More patients 
in the TA groups (4 mg-35%;1 mg-26%) required initiation 
of IOP-lowering drops compared to the observation group 
(8%). Significantly more patients in the 4 mg group (21) than 
in the observation group (3) required cataract surgery in the 
study eye between 1 and 2 years. The study recommended 
injection of 1 mg TA for patients with macular edema due to 
CRVO with repeat injections every 4 months for persistent/
recurrent edema. In the BRVO study, baseline characteristics 
were well balanced among the three groups; the mean age 
was 67 years, mean BCVA was 20/80, the mean time from 
diagnosis of BRVO was 4 months, and the mean CPT was 
525 µm. At month 12, the primary endpoint, mean change 
from baseline BCVA letter score was 5.7 (1 mg) and 4.0 
(4 mg) in the TA groups and 4.2 in the grid laser group. The 
percentage of patients who gained $ 15 letters in BCVA 
was 26% (1 mg) and 27% (4 mg) in the TA groups and 29% 
in the laser group. Thus, TA injections were not superior to 
grid laser.
The GENEVA Trials were two Phase III trials compar-
ing the effects of intraocular injection of 0.7 mg or 0.35 mg 
dexamethosone (DEX) implants to sham injections in patients 
with macular edema due to CRVO or BRVO.19 The trials 
were identical and therefore the pooled results were reported; 
0.7 mg (n = 427), 0.35 mg (n = 414), sham (n = 426). Patients 
were eligible if they had foveal-involved macular edema from 
a CRVO (1.5–9 months) or BRVO (1.5–12 months), BCVA 
of 20/50 to 20/200, and CST $ 300 µm (Stratus OCT2 or 
OCT3). Patients were excluded if they had glaucoma or 
ocular hypertension requiring more than one medication. 
Twice as many BRVO (n = 830, 66%) as CRVO (n = 437, 
34%) were enrolled. The design of this study is unusual. 
In   particular, data from the entire population which combines 
outcomes for CRVO and BRVO are difficult to interpret 
because of differences in their natural history; BRVO has a 
higher rate of spontaneous improvement of macular edema, 
lower rates of vitreous hemorrhage and neovascular glau-
coma which can adversely affect visual outcomes, and there 
are potential confounding effects from rescue grid laser. 
Therefore, the subgroup analyses provide the information 
most relevant to patient care.
In the BRVO subgroup at the 6-month primary   endpoint, 
the mean change from baseline BCVA letter score was 
7.5 in the two DEX implant groups compared to 5.0 in the 
sham group (P = 0.008). The percentage of patients who 
gained $ 15 letters in BCVA was 23% (0.7 mg) and 21% 
(0.35 mg) in the implant groups and 20% in the sham group. 
In the CRVO subgroup, the mean change from baseline 
BCVA letter score was 0 (0.7 mg) and 2 (0.35 mg) in the 
two DEX implant groups, not significantly better than sham 
(-2). The percentage of patients who gained $ 15 letters in 
BCVA was 18% (0.7 mg) and 17% (0.35 mg) in the implant 
groups and 12% in the sham group (NS). Thus, 6 months 
after injection there was little evidence of benefit in patients 
with BRVO and no benefit in CRVO. However, both patient 
populations showed some evidence of benefit at earlier time 
points. Peak effects were at 60 days. In the CRVO subgroup, 
the mean change from baseline BCVA letter score was 9 
(0.7 mg) and 10 (0.35 mg) in the two DEX implant groups, 
significantly better than sham (0), and 29% and 33% of 
patients gained $ 15 letters in BCVA compared to 9% for 
sham. At 3 months, the mean change from   baseline BCVA 
letter score was 4 (0.7 mg) and 6 (0.35 mg) in the two DEX 
implant groups, significantly better than sham (0), and 18% Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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and 24% of patients gained $ 15 letters in BCVA compared 
to 10% for sham. In the BRVO subgroup, the mean change 
from baseline BCVA letter score was 10 (0.7 mg) and 9 
(0.35 mg) in the two DEX implant groups, significantly better 
than sham (5), and 30% and 26% of patients gained $ 15 
letters in BCVA compared to 13% for sham. At 3 months, 
the mean change from baseline BCVA letter score was 9 
(0.7 mg) and 8 (0.35 mg) in the two DEX implant groups, 
significantly better than sham (5), and 24% and 23% of 
patients gained $ 15 letters in BCVA compared to 15% for 
sham. Based upon the shorter than anticipated duration of 
action of the DEX implants, it would be useful to know the 
effect of repeated injections at 3 month intervals and hope-
fully such a trial will be considered in the future. Tables 1 
and 2 show a comparison of outcomes from the BRAVO, 
CRUISE, SCORE, and Geneva trials.
Summary and recommendations
Recent studies have provided new options for the manage-
ment of CRVO and BRVO. For CRVO, we have gone from 
no treatments to three possible options. The options are not 
mutually exclusive but choices must be made based upon 
relative benefit/risk ratios as to which option becomes first-
line treatment and which take on adjunctive roles. Using 
separate trials to assess relative benefit/risk ratios can be 
hazardous because differences in patient populations and pro-
cedures can cloud the issue. In comparing the CRUISE and 
SCORE CRVO trials, it is clear that there were population 
differences, because the changes in mean BCVA letter score 
in control groups were different (CRUISE: 6 months, +0.8 
vs SCORE: 8 months, -11.7, 12 months, -12.1) and 17% of 
the CRUISE control group gained $ 15 letters compared to 
7% in SCORE. Differences in eligibility criteria may explain 
the differences. For CRUISE, patients were excluded for 
BCVA , 20/320 (compared to BCVA , 20/400 in SCORE), 
an afferent pupil defect, or CRVO . 1 year. The first two 
criteria may have limited the number of patients with poor 
visual prognosis (regardless of therapy) due to severe retinal 
ischemia. Duration of CRVO prior to initiation of treatment 
can negatively impact outcome16 and the mean duration of 
CRVO was 3.3 months in CRUISE compared to 4 months 
in SCORE.
The percentage of patients who gained $ 15 letters 
in BCVA was 46.2% (0.3 mg) and 47.7% (0.5 mg) in the 
ranibizumab groups and 16.9% in the corresponding control 
group, a difference of 28%–30%. The percentage of patients 
who gained $ 15 letters in BCVA was 26.5% (1 mg) and 
25.6% (4 mg) in the TA groups and 6.8% in the corresponding 
control group, a difference of 19%–20%. Thus, although the 
differences in study populations and design make comparison 
difficult, the relative benefit seems to be greater with ranibi-
zumab and considering the risk of cataract and increased IOP 
with TA, ranibizumab has a clear edge.
Differences in study design are the main   confounding 
factor in comparing ranibizumab with DEX implants. 
  Comparison of monthly injections of ranibizumab to a single 
injection of a DEX implant at 6 months is easy, because 
the mean change from baseline BCVA letter score was 0 
(0.7 mg) and 2 (0.35 mg) in the two DEX implant groups, 
not significantly better than their control group (-2). It is 
anticipated that two DEX implant injections 3 months apart 
would provide greater efficacy, but could also result in greater 
toxicity. Therefore, with our current state of knowledge, 
ranibizumab is favored for primary therapy.
Our recommendation for CRVO is to give six injections 
of  0.5 mg ranibizumab at monthly intervals. After 6 months, 
it is best to continue monthly follow-up visits and ranibi-
zumab injections for recurrent edema have been shown to 
maintain visual benefit to at least 1 year.14 Some patients 
continue to have recurrent edema after 1 year or longer 
of treatment16 and we do not yet have a guide as to how to 
manage such patients. An ongoing clinical trial is investi-
gating whether laser photocoagulation to areas of capillary 
nonperfusion can reduce the frequency of ranibizumab injec-
tions required. Although most patients respond quite well to 
ranibizumab injections, in the rare cases where patients who 
have substantial residual edema and reduced vision after six 
sessions of monthly injections, it would be reasonable to con-
sider a DEX implant. Ranibizumab levels may decline more 
rapidly in vitrectomized eyes, so the threshold may be lower 
for considering a DEX implant in a vitrectomized eye that 
appears to be responding poorly to ranibizumab injections. 
Hopefully future studies will provide guidance regarding 
combination therapy in patients who respond suboptimally 
to ranibizumab injections.
The comparative analysis is very similar for patients 
with BRVO and favors ranibizumab; however, integration 
of drug treatment with grid laser therapy is an additional 
consideration. Visual acuity improves rapidly after injec-
tion of ranibizumab whereas benefit occurs slowly after grid 
laser therapy and the presence of intraretinal hemorrhages 
in the macula often precludes laser for several months. 
Our recommendation for BRVO with macular edema is 
to give six sessions of monthly injections of ranibizumab. 
This has the advantage of causing more rapid clearing of 
hemorrhages in addition to improving vision and macular Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Comparison of outcomes of recent clinical trials on treatment of CRvO
CRUISE SCORE GENEVA
CRVO CRVO
N 392 271 437
Primary  
endpoint
Month 6 Month 12 Month 6
Arms 0.3 mg   
RBZ
0.5 mg   
RBZ
Sham 1 mg   
TA
4 mg  
TA
Observe 0.7 mg 
DeX
0.35 mg 
DeX
Sham
Mean ∆BCvA 12.7 14.9 0.8 -1.2 -1.2 -12.1 0 2 -2
% $15  
letters gained
46.2 47.7 16.9 26.5 25.6 6.8 18 17 12
% $15  
letters lost
25.6 25.3 43.8
% snellen 20/40  
or better
43.9 46.9 20.8
% snellen vA  
20/200 or worse
15.2 11.5 27.7
improvement  
in Nei-vFQ-25
7.1 6.2 2.8
Mean change in  
CPT/µm
434 452 168
Median change  
in CPT/µm
196 261 277
% CPT # 250 75 77 23 32 45 28
Abbreviations: ∆BCvA, change in best corrected visual acuity; CPT, central point thickness; DeX, dexamethasone implant; RBZ, ranibizumab; TA, triamcinolone.
Table 2 Comparison of outcomes of recent clinical trials on treatment of BRvO
BRAVO SCORE GENEVA
BRVO BRVO
N 397 411 830
Primary  
endpoint
Month 6 Month 12 Month 6
Arms 0.3 mg
RBZ
0.5 mg 
RBZ
Sham 1 mg   
TA
4 mg  
TA
Grid 
laser
0.7 mg 
DeX
0.35 mg 
DeX
Sham
Mean ∆BCvA 16.6 18.3 7.3 5.7 4 4.2 7.5 7.5 5
% $15  
letters gained
55.2 61.1 28.8 26 27 29 23 21 20
% $15  
letters lost
5.7 4.0 14.9
% snellen 20/40  
or better
67.9 64.9 41.7
% snellen vA  
20/200 or worse
1.5 0.8 9.1
improvement  
in Nei-vFQ-25
9.3 10.4 5.4
Mean change in  
CPT/µm
337 345 158
Median change  
in CPT/µm
149 170 224
% CPT # 250 91 85 46 37 45 53
Abbreviations: ∆BCvA, change in best corrected visual acuity; CPT, central point thickness; DeX, dexamethasone implant; RBZ, ranibizumab; TA, triamcinolone.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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edema.15 Even the small   percentage of patients that would 
have   experienced spontaneous improvement obtain benefit 
from more rapid return of vision. If there is recurrent edema 
after six ranibizumab injections, it is reasonable to consider 
grid laser therapy in combination with ranibizumab as 
needed. If despite grid laser treatment, frequent injections 
of ranibizumab continue to be needed to control edema after 
1 year, it would be reasonable to discuss the pros and cons 
of a DEX implant with the patient.
Questions and future directions
Our understanding of RVOs has greatly increased over 
the past few years, but there are still many remaining 
questions. 1) Can bevacizumab be substituted for ranibi-
zumab? 2) Can higher doses of ranizibumab provide 
greater benefit than that seen with 0.5 mg? 3) What role 
will VEGF-Trap Eye play in management in the future? 
4) What is the role of peripheral capillary nonperfusion in 
the development, persistence, and recurrence of edema, 
and can scatter photocoagulation to areas of nonperfusion 
provide benefit? 5) Do other pro-permeability factors in 
addition to VEGF play a role in RVO and do they account 
for residual edema seen in some patients treated with anti-
VEGF agents? One way to address this issue is to measure 
aqueous levels of pro-permeability factors in RVO patients 
that have residual edema despite intensive treatment with 
an anti-VEGF agent. The feasibility of this approach has 
been demonstrated in a small study,20 but a larger study 
is needed. 6) Are there strategies that can promote per-
manent resolution of edema and reduce the duration of 
anti-VEGF injections required? The   Ranibizumab DosE 
Comparison (0.5 mg and 2.0 mg) and the Role of LAser in 
the   ManagemenT of REtinal Vein Occlusion – (RELATE) 
study is currently recruiting patients with BRVO and 
CRVO. It seeks to determine if six sessions of monthly 
injections of 2.0 mg of ranibizumab provides superior out-
comes compared to six injections of 0.5 mg. At 6 months, 
there is a second randomization to determine if laser 
photocoagulation to areas of capillary nonperfusion can 
help to achieve complete resolution of edema with fewer 
ranizibumab injections and whether visual benefits are 
maintained despite laser treatment. Hopefully this study 
and others will provide additional guidance as to how our 
treatment regimens can be modified to further enhance 
the outstanding outcomes that are being achieved while at 
the same time reducing burden of frequent follow-up and 
injections in our patients with RVO.
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